Abstract 1195P
Background
Li-Fraumeni syndrome (LFS) is a rare autosomal dominant condition, caused by an alteration in the TP53 gene. Individuals with LFS are susceptible to developing a wide range of malignancies. National and international guidelines recommend annual WB-MRI scan for screening for cancer; however, WB-MRI is not yet implemented in this setting worldwide or in the UK. SIGNIFIED is a cost-effectiveness and implementation project that will assess the value of screening WB-MRI in LFS.
Methods
Individuals with LFS, with no cancer diagnosis in the past 5 years, were scanned using two WB-MRI, 12 months apart. Diffusion-weighted MRI images were acquired from vertex to feet. Incidental findings were further investigated and discussed in a specialist MDT meeting.
Results
Fifty-four asymptomatic individuals with LFS were recruited between May 2022 and July 2023 from Cancer Genetic Units across the United Kingdom. 40 females (74%) and 14 males (26%) were enrolled. The median age at recruitment was 42 years (range 18-70). Following 1st scan performed in 54 individuals, 16.6% of patients had a suspicious lesion that was biopsied/excised (N=9), and less than half (44%, N=4) had a confirmed cancer. Following 2nd scan performed in 44 individuals, 13.6% of patients had a suspicious lesion that was biopsied/excised (N=6) and in 83% of cases (N=5), a cancer diagnosis was confirmed. There was increased confidence in benignity when a comparator scan was available. In total, 9 cancers were detected and 66% (N=6) were diagnosed at stages 0-2 and underwent curative treatment. A further stage 3 pancreatic cancer (T4N0M0) was diagnosed and the patient received peri-operative chemotherapy and surgery with curative intent.
Conclusions
Overall, 9 cancers in 54 individuals were diagnosed with the help of WB-MRI. The rate of cancers detected in this cohort was higher than expected in a general population, consistent with the known risk of cancers in the LFS population. WB-MRI is a valuable and useful radiological tool for the detection of early cancers in LFS and our data support guidelines that it should be implemented as a regular screening test for this population. A health economics analysis is currently ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Small Business Research Initiative (SBRI) Healthcare.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
707P - Paclitaxel, ifosfamide and cisplatin (TIP) in patients (pts) with poor prognosis nonseminomatous germ cell tumor (NSGCT) with unfavourable serum tumor markers (STM) decline: A phase II study
Presenter: Edgar Israelyan
Session: Poster session 09
708P - The Empower Pathway: An audit of the first 150 patients. Enhanced personalised care of testicular cancer survivors
Presenter: Penny Champion
Session: Poster session 09
817P - A machine learning algorithm utilizing clinicopathologic parameters for extranodal natural killer/T cell lymphoma
Presenter: Shuo Li
Session: Poster session 09
Resources:
Abstract
818P - The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy
Presenter: Z.L.Rana Kaplan
Session: Poster session 09
819P - Efficacy and safety of orelabrutinib plus R-CHOP-like regimens for treatment-naïve diffuse large B-cell lymphoma with double expression
Presenter: Wei Wan
Session: Poster session 09
820P - Second primary malignancies and disease transformation in symptomatic patients with Waldenstrom’s macroglobulinemia: Outcomes of a population-based analysis
Presenter: Vasiliki Spiliopoulou
Session: Poster session 09
821P - Circulating chromosomal alterations in lymphoid malignancies
Presenter: Rosalie Griffin
Session: Poster session 09
822P - Preliminary results from a phase Ib study of amulirafusp alfa (IMM0306) in combination with lenalidomide in patients with relapsed or refractory CD20-positive B-cell non-Hodgkin's lymphoma
Presenter: Lijuan Deng
Session: Poster session 09
823P - The bone marrow immune ecosystem shapes acquired resistance to daratumumab in plasma cell myeloma
Presenter: Yun Wang
Session: Poster session 09
824P - FLT3-ITD induces immune escape in AML via up-regulating CD47 expression and decreased phagpcytic ability of macrophages
Presenter: Shuzhao Chen
Session: Poster session 09